Answers are grounded in this paper and cite their sources.
Economic evaluation shows cost-effectiveness of tislelizumab in unresectable hepatocellular carcinoma, suggesting efficient resource allocation in healthcare.
For uHCC in China, tislelizumab represents a cost-effective choice at the current willingness-to-pay threshold of $40,344 per QALY (3×gross domestic product (GDP) per capita). This analysis provides timely evidence to inform clinical practice and policy decisions regarding the allocation of finite healthcare resources.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: